Robert Hazlett
Stock Analyst at BTIG
(0.87)
# 3,253
Out of 4,667 analysts
25
Total ratings
35.48%
Success rate
-17.44%
Average return
Main Sectors:
Stocks Rated by Robert Hazlett
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AURA Aura Biosciences | Maintains: Buy | $21 → $24 | $8.75 | +174.29% | 3 | Oct 18, 2024 | |
| NKTR Nektar Therapeutics | Assumes: Buy | $4 | $1.00 | +300.00% | 2 | Sep 30, 2024 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $7 → $14 | $2.05 | +582.93% | 2 | May 9, 2024 | |
| LYRA Lyra Therapeutics | Maintains: Buy | $24 → $20 | $0.18 | +11,135.96% | 1 | Feb 7, 2023 | |
| AXSM Axsome Therapeutics | Maintains: Buy | $62 → $98 | $94.60 | +3.59% | 2 | Dec 23, 2022 | |
| VSTM Verastem | Maintains: Buy | $96 → $60 | $3.79 | +1,483.11% | 3 | Oct 5, 2022 | |
| CMPS COMPASS Pathways | Initiates: Buy | $63 | $4.66 | +1,251.93% | 1 | May 27, 2021 | |
| PRTA Prothena Corporation | Upgrades: Buy | $29 | $14.40 | +101.39% | 4 | Feb 2, 2021 | |
| ITCI Intra-Cellular Therapies | Maintains: Buy | $80 → $40 | $85.64 | -53.29% | 2 | Nov 2, 2020 | |
| RDHL RedHill Biopharma | Initiates: Buy | $26,000 | $6.40 | +406,150.00% | 1 | Sep 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $26 → $6 | $1.79 | +235.20% | 2 | Sep 4, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $18 → $27 | $8.96 | +201.34% | 2 | Oct 16, 2017 |
Aura Biosciences
Oct 18, 2024
Maintains: Buy
Price Target: $21 → $24
Current: $8.75
Upside: +174.29%
Nektar Therapeutics
Sep 30, 2024
Assumes: Buy
Price Target: $4
Current: $1.00
Upside: +300.00%
Rani Therapeutics Holdings
May 9, 2024
Maintains: Buy
Price Target: $7 → $14
Current: $2.05
Upside: +582.93%
Lyra Therapeutics
Feb 7, 2023
Maintains: Buy
Price Target: $24 → $20
Current: $0.18
Upside: +11,135.96%
Axsome Therapeutics
Dec 23, 2022
Maintains: Buy
Price Target: $62 → $98
Current: $94.60
Upside: +3.59%
Verastem
Oct 5, 2022
Maintains: Buy
Price Target: $96 → $60
Current: $3.79
Upside: +1,483.11%
COMPASS Pathways
May 27, 2021
Initiates: Buy
Price Target: $63
Current: $4.66
Upside: +1,251.93%
Prothena Corporation
Feb 2, 2021
Upgrades: Buy
Price Target: $29
Current: $14.40
Upside: +101.39%
Intra-Cellular Therapies
Nov 2, 2020
Maintains: Buy
Price Target: $80 → $40
Current: $85.64
Upside: -53.29%
RedHill Biopharma
Sep 11, 2020
Initiates: Buy
Price Target: $26,000
Current: $6.40
Upside: +406,150.00%
Sep 4, 2020
Maintains: Buy
Price Target: $26 → $6
Current: $1.79
Upside: +235.20%
Oct 16, 2017
Maintains: Buy
Price Target: $18 → $27
Current: $8.96
Upside: +201.34%